| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Rapamycin has been used in drug-eluting stents to prevent restenosis. The mechanism that underlies rapamycin's potent effect on intimal hyperplasia is inhibition of mTOR. Inhibiton of mTOR decreases proliferation and migration, stimulates apoptosis. After siRNA mTOR is transfected into vascular smooth muscle cells derived from coronary artery or aorta, siRNA inhibits phosprylation of S6Kinase which is downstream of mTOR. We can see a localized severely calcified stenosis in the anastmosis site. The graft occulusion is also caused by vascular calcifications. Computed tomography (CT) is useful for identifying vascular calcification. We find vascular calcification is more sevre in patients with diabetes mellitus or hemodialysis.
|
